Yahoo Finance

European Commission approves RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small ...

BEERSE, BELGIUM, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Type II variation ...
Yahoo Finance

RYBREVANT® (amivantamab) plus LAZCLUZE® (lazertinib) reduces acquired resistance versus osimertinib in first-line EGFR-mutated advanced non-small cell lung cancer

BEERSE, BELGIUM , Sept. 06, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced new analyses from the Phase 3 MARIPOSA study showing that first-line ...
The American Journal of Managed Care

Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody. Data from the MARIPOSA study (NCT04487080) support this newest approval, and ...
PharmaTimes

EC approves lazertinib in combination with amivantamab for NSCLC patients

The European Commission (EC) has approved the marketing authorisation for LAZCLUZE (lazertinib) in combination with RYBREVANT (amivantamab) for the first-line treatment of adult patients with advanced ...
PharmiWeb

CHMP recommends RYBREVANT® (amivantamab) in combination with LAZCLUZE® (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer

The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients with advanced NSCLC with EGFR ex19del or L858R substitution ...
The Korea Herald

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian ...

SINGAPORE, Dec. 8, 2025 First and only chemotherapy-free combination in the first-line setting to demonstrate an overall survival benefit versus osimertinib among Asian patients. Median overall ...
PharmaTimes

Amivantamab plus lazertinib shows survival benefit in lung cancer

Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study, demonstrating a significant overall survival benefit for patients with EGFR-mutated advanced non-small cell lung ...
PharmiWeb

European Commission approves LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small ...

Latest topline data from the Phase 3 MARIPOSA study shows amivantamab plus lazertinib is the first regimen to demonstrate superior overall survival benefit compared to the current standard of care ...
Mena FN

RYBREVANT® (Amivantamab) Plus LAZCLUZE® (Lazertinib) Reduces Acquired Resistance Versus Osimertinib In First-Line EGFR-Mutated Advanced Non-Small Cell Lung Cancer

(MENAFN- GlobeNewsWire - Nasdaq) New data demonstrate amivantamab combination significantly reduces common EGFR and MET resistance mutations seen with EGFR TKIs 1 Resistance to EGFR tyrosine kinase ...
Mena FN

European Commission Approves RYBREVANT® (Amivantamab) In Combination With LAZCLUZE® (Lazertinib) For The First-Line Treatment Of Patients With EGFR-Mutated Advanced Non-Small ...

Lazertinib is an oral, third-generation, brain-penetrant EGFR TKI that targets both the T790M mutation and activating EGFR mutations while sparing wild-type EGFR.17 An analysis of the efficacy and ...
manilatimes

European Commission approves LAZCLUZE® (lazertinib) in combination with RYBREVANT® (amivantamab) for the first-line treatment of patients with EGFR-mutated advanced non-small ...

BEERSE, BELGIUM, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the European Commission (EC) has approved a Marketing Authorisation ...